Amid the threat of pharmaceutical tariffs from President Donald Trump, recent months have seen multibillion-dollar U.S.

Cobenfy, the novel antipsychotic drug that Bristol Myers Squibb obtained from a $14 billion acquisition, could have a problem ...

Sprout Pharmaceuticals is once again under fire from the FDA’s Office of Prescription Drug Promotion (OPDP). | Sprout ...

For the second time in nine months, a Delaware judge has sided (PDF) with Syntimmune shareholders over AstraZeneca, granting ...

Havas Media Network has set up an advertising marketplace to help companies reach patients who are cut off from healthcare by ...

GSK is putting the finishing touches on its case for antibody-drug conjugate Blenrep with a key progression-free survival ...

Despite an outcry from the biopharmaceutical industry, the U.K. government has kept the rebate rate under a national ...

Hoping to gain an edge in the rapidly growing market are MilliporeSigma and Simtra BioPharma Solutions, which have forged a ...

With great power comes great responsibility, and Insulet, accordingly, is using its influence in the diabetes management ...

After combining on the development of five malaria vaccine candidates since 2016, Swedish CDMO Recipharm and the University ...

Travere Therapeutics has turned music mogul, bringing together a singer-songwriter and Grammy-winning producer to create an ...

With what Insmed calls an "outstanding" phase 2 win for its treprostinil palmitil inhalation powder (TPIP) in patients with ...